Transgene Announces Upcoming Investor Meetings
18 mars 2024 12h45 HE
|
Transgene S.A.
Strasbourg, March 18, 2024 - 05:45 pm CET TRANSGENE (Paris: TNG) today announces that Management will participate in several investor events in the upcoming months, as set out below. Investor Access...
Transgene présentera de nouvelles données sur son vaccin individualisé TG4050 à l’AACR 2024
06 mars 2024 01h30 HE
|
Transgene S.A.
Présentation d’un poster contenant de nouvelles donnéesde l’essai randomisé de Phase I de TG4050 dans les cancers de la tête et du cou Strasbourg, France, le 06 mars 2023, 7 h 30 — Transgene...
Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
06 mars 2024 01h30 HE
|
Transgene S.A.
Poster presentation of new data from ongoing randomized Phase I trial targeting head and neck cancers Strasbourg, France, March 6, 2024, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a...
Transgene, NEC et BostonGene étendent leur collaboration dans le cadre de l’essai clinique de Phase I/II du vaccin individualisé TG4050
05 mars 2024 01h30 HE
|
Transgene S.A.
Strasbourg (France), Tokyo (Japon), Waltham (Mass. USA) – le 5 mars 2024, 7h30 - Transgene (Euronext Paris : TNG), une société de biotechnologie qui conçoit et développe des immunothérapies du cancer...
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
05 mars 2024 01h30 HE
|
Transgene S.A.
Strasbourg (France), Tokyo (Japan) and Waltham, Mass (USA), March 5th, 2024, 7:30 am CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for...
Transgene annonce la nomination de James Wentworth comme Directeur du Business Development
22 janv. 2024 11h45 HE
|
Transgene S.A.
Strasbourg, France – Le 22 janvier 2023, 17 h 45 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies contre le cancer reposant sur des vecteurs...
Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer
22 janv. 2024 11h45 HE
|
Transgene S.A.
Strasbourg, France, January 22, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased...
Transgene présente son calendrier de communication financière pour 2024
22 janv. 2024 02h00 HE
|
Transgene S.A.
Strasbourg, le 22 janvier 2024, 08h00 TRANSGENE (Paris : TNG) communique aujourd’hui son calendrier de communication financière pour 2024 : 27 mars 2024 : Résultats annuels...
Transgene Announces Financial Calendar for 2024
22 janv. 2024 02h00 HE
|
Transgene S.A.
Strasbourg (France), January 22, 2024 - 08:00 am CET TRANSGENE (Paris: TNG) today announced its financial reporting dates for 2024. March 27, 2024: 2023 Fiscal Year Results May 14,...
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
08 janv. 2024 11h45 HE
|
Transgene S.A.
Transgene and NEC plan to start an extension of the randomized Phase I trial into a randomized Phase I/II study in 2024 to further demonstrate the potential of TG4050 as an adjuvant treatment of...